Variant profiling of candidate genes in pancreatic ductal adenocarcinoma

Clinical Chemistry

Volumn 61, Issue 11, 2015, Pages 1408-1416

  Huang, Jiaqi ^a   Löhr, Johannes Matthias ^b   Nilsson, Magnus ^b   Segersvärd, Ralf ^b   Matsson, Hans ^a   Verbeke, Caroline ^a,b   Heuchel, Rainer ^b   Kere, Juha ^a   Iafrate, A John ^c   Zheng, Zongli ^a,c,d   Ye, Weimin ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d CITY UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN P53; SMAD4 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UVOMORULIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; SMAD4 PROTEIN, HUMAN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANCHORED MULTIPLEX POLYMERASE CHAIN REACTION; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA BASE COMPOSITION; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; NEXT GENERATION SEQUENCING; ONCOGENE N RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; POPULATION BASED CASE CONTROL STUDY; SMOKING; SURVIVAL TIME; TARGETED SEQUENCING PLATFORM; TUMOR GENE; CARCINOMA, PANCREATIC DUCTAL; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PANCREAS DUCT; PANCREATIC NEOPLASMS; PATHOLOGY; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SMAD4 PROTEIN; SMOKING; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84946553595     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.238543     Document Type: Article

References (41)

1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol 2014;25: 1650-6.
2. Mimeault M, Brand RE, Sasson AA, Batra SK. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 2005;31: 301-16.
3. Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 2005;70: 65-72.
4. Jaffee EM, Hruban RH, Canto M, Kern SE. Focus on pancreas cancer. Cancer Cell 2002;2: 25-8.
5. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol 2008;3: 157-88.
6. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321: 1801-6.
7. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012;491: 399-405.
8. Wang L, Tsutsumi S, Kawaguchi T, Nagasaki K, Tatsuno K, Yamamoto S, et al. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res 2012;22: 208-19.
9. Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med 2014;20: 1479-84.
10. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010; 26: 589-95.
11. Wang K, Li M, Hakonarson H. Annovar: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38: E164.
12. Quinlan AR, Hall IM. Bedtools: A flexible suite of utilities for comparing genomic features. Bioinformatics 2010;26: 841-2.
13. Quantitative multiplex-DNA reference standards. http://www.horizondx.com/quantitative-multiplex-dnareference-standards.html (Accessed August 2015).
14. Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, Muendlein A. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn 2011;13: 23-8.
15. Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, Marko AC, et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffinembedded and fine-needle aspiration tumor specimens. J Mol Diagn 2013;15: 234-47.
16. de Biase D, Visani M, Baccarini P, Polifemo AM, Maimone A, Fornelli A, et al. Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions. PLoS One 2014;9: E87651.
17. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun 2013;4: 2185.
18. Rachakonda PS, Bauer AS, Xie H, Campa D, Rizzato C, Canzian F, et al. Somatic mutations in exocrine pancreatic tumors: Association with patient survival. PLoS One 2013;8: E60870.
19. Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(ink4a), p21(waf-1), cyclin d1, erbb-2 and erbb-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000;89: 469-74.
20. Dergham ST, Dugan MC, Kucway R, Du W, Kamarauskiene DS, Vaitkevicius VK, et al. Prevalence and clinical significance of combined k-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol 1997;21: 127-43.
21. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutantenriched polymerase chain reaction analysis and allelespecific oligonucleotide hybridization. Am J Pathol 1993;143: 545-54.
22. Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB, Luttges J. Frequency of k-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: A metaanalysis. Neoplasia 2005;7: 17-23.
23. Immervoll H, HoemD, Kugarajh K, Steine SJ, Molven A. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: Lack of mutations in the BRAF and EGFR genes. Virchows Arch 2006;448: 788-96.
24. Ogura T, Yamao K, Hara K, Mizuno N, Hijioka S, Imaoka H, et al. Prognostic value of k-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol 2013;48: 640-6.
25. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: The multicenter 'RASCAL' study. J Natl Cancer Inst 1998;90: 675-84.
26. Vega F, Iniesta P, Caldes T, Sanchez A, Lopez J, Dejuan C, et al. Association of k-ras codon 12 transversions with short survival in non-small cell lung cancer. Int J Oncol 1996;9: 1307-11.
27. Keohavong P, DeMichele MA, Melacrinos AC, Landreneau RJ, Weyant RJ, Siegfried JM. Detection of k-ras mutations in lung carcinomas: Relationship to prognosis. Clin Cancer Res 1996;2: 411-8.
28. Al-Mulla F, Milner-White EJ, Going JJ, Birnie GD. Structural differences between valine-12 and aspartate-12 ras proteins may modify carcinoma aggression. J Pathol 1999;187: 433-8.
29. Krengel U, Schlichting I, Scherer A, Schumann R, Frech M, John J, et al. Three-dimensional structures of h-ras p21 mutants: Molecular basis for their inability to function as signal switch molecules. Cell 1990;62: 539-48.
30. Al-Mulla F, MacKenzie EM. Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol 2001;195: 549-56.
31. Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G, et al. Disruption of the antiproliferative TGFbeta signaling pathways in human pancreatic cancer cells. Oncogene 1998;17: 1969-78.
32. Truty MJ, Urrutia R. Basics of TGF-beta and pancreatic cancer. Pancreatology 2007;7: 423-35.
33. Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, Zhang X, et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res 2009;69: 3681-8.
34. Crous-Bou M, Porta M, Lopez T, Jariod M, Malats N, Alguacil J, et al. Lifetime history of tobacco consumption and k-ras mutations in exocrine pancreatic cancer. Pancreas 2007;35: 135-41.
35. Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003;124: 1292-9.
36. Raimondi S, Maisonneuve P, Lohr JM, Lowenfels AB. Early onset pancreatic cancer: Evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomarkers Prev 2007;16: 1894-7.
37. Jiao L, Zhu J, Hassan MM, Evans DB, Abbruzzese JL, Li D. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: In relation to cigarette smoking. Pancreas 2007;34: 55-62.
38. Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K, Miller MS. The cyclooxygenase inhibitor ibuprofen and the flap inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol 2002;128: 525-32.
39. Hainaut P, Pfeifer GP. Patterns of p53 G T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001;22: 367-74.
40. Diergaarde B, Vrieling A, van Kraats AA, van Muijen GN, Kok FJ, Kampman E. Cigarette smoking and genetic alterations in sporadic colon carcinomas. Carcinogenesis 2003;24: 565-71.
41. Phipps AI, Shi Q, Newcomb PA, Nelson GD, Sargent DJ, Alberts SR, Limburg PJ. Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III trial N0147. J Clin Oncol 2013;31: 2016-23.